Growth inhibition of human glioma cells by superinduced human interferon-beta.
Superinduction of human interferon-beta (HuIFN-beta) from human glioma cells has greater cytotoxicity than purified HuIFN-beta derived from fibroblasts. However, superinduction requires several reagents like polyI:polyC, cycloheximide, and actinomycin D, which may contaminate the conditioned medium and obscure the effect of superinduced HuIFN-beta. The present study used minimum doses of polyI:polyC and cycloheximide without actinomycin D to superinduce HuIFN-beta. The superinduced HuIFN-beta was purified by passing the medium through molecular sieve column chromatography. Fractionation of the eluate provided semipurified superinduced HuIFN-beta which demonstrated a growth inhibitory effect against both the U251-MG autologous human glioma cell line and the SK-MG-1 homologous glioma cell line. This effect was neutralized by addition of anti-HuIFN-beta monoclonal antibody (YSB-1). In a separate experiment, combinations of superinduction reagents were found not to have growth inhibitory effects because all inhibition in superinduced medium was completely neutralized by YSB-1. Superinduced HuIFN-beta has a pure growth inhibitory effect on both autologous and homologous glioma cells, so may affect autocrine secretion of cytokines.
Nehashi
K
K
Department of Neurosurgery, Nagoya University School of Medicine, Japan.
Yoshida
J
J
Wakabayashi
T
T
Nagata
M
M
Utsumi
J
J
Naruse
N
N
Sugita
K
K
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects*; D002478:Cells, Cultured; D002845:Chromatography; D003513:Cycloheximide / Q000494:pharmacology; D003609:Dactinomycin / Q000494:pharmacology; D005910:Glioma / Q000473:pathology*; D006801:Humans; D016899:Interferon-beta / Q000378:metabolism / Q000494:pharmacology*; D009457:Neuroglia / Q000187:drug effects; D011066:Poly C / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D003609:Dactinomycin; D011066:Poly C; D016899:Interferon-beta; D003513:Cycloheximide